Kaye Mark has recently filed a Form 144, indicating a proposed sale of securities. This filing is significant as it reflects the company's strategic financial decisions and ongoing activity within the financial services industry.
Background
Kaye Mark operates as an entity in the financial services sector. The company is identified by its Central Index Key (CIK) number 0001748691. Recent filings include a Form 4 filed on October 23, 2026, and the current Form 144 filed on October 22, 2026.
What the Filing Says
The filing states that Kaye Mark has proposed a sale of securities, although specific details regarding the amount or type of securities were not disclosed. The filing was accepted on the same day, October 22, 2026, at 16:03:27.
Impact
This proposed sale may affect various stakeholders, including investors and competitors in the hospital and medical service plans sector. The filing indicates Kaye Mark's intent to engage in financial activities that could influence market dynamics.
What's Next
The filing does not say what happens next.
Details of the Filing
The Form 144 filing indicates that Kaye Mark is associated with Elevance Health, Inc., which is identified by its Central Index Key (CIK) number 0001156039. This connection may provide insights into the strategic direction of Kaye Mark, particularly in relation to its operations in the hospital and medical service plans sector.
Company Information
Kaye Mark's business address is listed as 220 Virginia Avenue, Indianapolis, IN 46204. This location may serve as a central hub for its financial activities and strategic initiatives.
Regulatory Context
The filing is classified under the Securities Act of 1933, which governs the registration of securities and the disclosure of information to investors. This regulatory framework is crucial for maintaining transparency and trust in the financial markets.
Filing Acceptance
The Form 144 was accepted by the SEC on October 22, 2026, at 16:03:27. This timestamp indicates the precise moment the filing was recognized, which is essential for tracking compliance and regulatory timelines.
Absence of Specifics
The filing does not provide specific details regarding the number of securities to be sold or the intended use of proceeds from the sale. Such information would be critical for stakeholders seeking to understand the implications of this proposed sale.